Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

May 01, 1998; 50 (5) Editorials

Metrifonate for Alzheimer's disease

Is the next cholinesterase inhibitor better?

David S. Knopman
First published May 1, 1998, DOI: https://doi.org/10.1212/WNL.50.5.1203
David S. Knopman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Metrifonate for Alzheimer's disease
Is the next cholinesterase inhibitor better?
David S. Knopman
Neurology May 1998, 50 (5) 1203-1205; DOI: 10.1212/WNL.50.5.1203

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
55

Share

  • Article
  • Info & Disclosures
Loading

Treatment of Alzheimer's disease (AD) is one of the great challenges to neuroscience for the 21st century. Despite intense investigation since the late 1970s, AD research has not provided a cure or therapy that permanently arrests the disease. Yet, over the past 10 years, there has been a considerable effort directed toward finding palliative therapies for AD that act through enhancement of cholinergic neuro-transmission. Therapy with cholinesterase inhibitors (CEIs) clearly affects the symptomatic expression of AD, but the practical benefits have been unclear.

Two articles1,2 in this issue of Neurology present data from clinical trials with the CEI metrifonate for the treatment of AD. Metrifonate has been available for many years as a treatment for schistosomaisis. In the late 1980s, it was suspected that as a CEI, metrifonate might have activity against AD.3 Recognition of its potential led to the current studies of metrifonate. The results provide additional confirmation of the CEI effect. Unfortunately, metrifonate's benefits are no greater than those of other CEIs.

Metrifonate's pharmacology is unique among the CEIs being used or considered for AD. It has a short half-life in plasma (2 hours) but a very long action in the brain because it is an irreversible CEI. It lacks specificity for central versus peripheral cholinesterases. Metrifonate is largely unbound to plasma proteins (<15%) and is not metabolized through the hepatic P450 system. Donepezil,4,5 tacrine,6 and rivastigmine,7 another CEI currently awaiting FDA approval, have different pharmacologic profiles. Which is the best profile? The clinical efficacy would suggest that none of these features make a difference across the CEIs. Patient tolerability differs, however.

The current studies used accepted diagnostic criteria and disease severity assessments. Both were placebo-controlled, randomized trials. Dropout rates were low, and as a consequence, an intent-to-treat analytic strategy adequately reflected the drug's effects. Nearly 90% of patients randomized to metrifonate completed the 12-week study1 and nearly 80% completed the 24-week study.2 The retention rates for metrifonate were comparable to donepezil8 but superior to tacrine.9

After 12 weeks of treatment, there was a nearly 3-point benefit for metrifonate over placebo1 on the Alzheimer's Disease Assessment Scale (ADAS-cog).10 This effect was sustained up to 24 weeks.2 Comparisons with other CEIs must be undertaken with caution as the drugs were not tested concurrently. With that caveat, metrifonate, tacrine,9 donepezil,8 and rivastigmine7 have produced similar changes on the ADAS-cog: from slightly less than 3 points to about 5 points compared to placebo over 6 months. Furthermore, changes on the clinician's global assessment ratings11 were also similar despite methodologic differences in the studies. The Clinician's Interview-Based Impression of Change (CIBIC) ratings for all the CEIs have been in the range of 0.25 and 0.5 rating points at 6 months. The effect of metrifonate on the Mini-Mental State Examination (MMSE) compared to the placebo group was positive; modest in the 12-week study1 but not in the 26-week.2 Again, the effects of the other agents on the MMSE are comparable to metrifonate's.

There are multiple demonstrations of efficacy of this class of drug in AD. Although the validity of the initial results with tacrine9 were questioned, the subsequent publication of trials for donepezil,8 now metrifonate,1,2 and the abstract presentation of rivastigmine7 form a broad foundation of support for the reality of the CEI effect in AD. Data from shorter trials of controlled-release physostigmine12 and galanthamine13 add further evidence for a consistent effect of CEIs on cognition and on global assessments. Nonetheless, because metrifonate's efficacy is not substantially greater than the others, questions about the "value" of CEI use in AD remain unresolved for some observers.

Metrifonate did not produce statistically significant effects on measures of activities of daily living. There are three possible explanations for this observation. One is that the drug's effect is too small. Another is that the duration of therapy was too short to observe differences with treatment. A third possibility is that the wrong measurement tool was used. The combination of a relatively small effect of the drugs plus the short period of study probably accounts for the inconsistent effects of CEIs on daily living skills. Unfortunately, functional assessment is an area for which there is no consensus on the best instrument for measuring change in clinical trials. The trials of donepezil,8 metrifonate,1,2 and tacrine9 all worked with different assessment tools. It is simply not possible to make claims about similarities or differences of effects on daily functioning among the different CEIs. Although improvement or stabilization in functional effectiveness of an AD patient is a major goal of therapy, measurement of this ability has been difficult. Galasko et al.14 have devised a new activities of daily living scale specifically for use in clinical trials. Widespread use in a single instrument would allow rough comparisons across studies.

The 26-week metrifonate study provided the first prospective evidence for beneficial effects of a CEI on mood and behavior in a controlled trial. A prior open-label study of tacrine15 and a secondary analysis of the 30-week tacrine study16 suggested this finding. A study of the muscarinic agonist xanomeline17 was the first study of a cholinomimetic drug to observe the effect in a double-blind trial. In one of the current studies,2 the Neuropsychiatric Inventory (NPI),18 a measure of behavioral abnormalities associated with AD, showed benefits of metrifonate therapy compared to placebo for ratings of apathy, dysphoria, and hallucinations. The observations from metrifonate and the other sources15-17 lead to interesting speculation on the interplay between cognitive effects and alterations in mood and initiative brought about by metrifonate and perhaps other CEIs. Unfortunately, it is not possible to determine whether the cognitive benefits cause improved behavior or vice versa. More must be learned about the noncognitive effects of cholinomimetic drugs. The question has important bearing on understanding of the mechanism of action of these agents.

Most metrifonate-treated patients remained on drug for the entire study. They experienced a low incidence of gastrointestinal side effects. Metrifonate appeared comparable to donepezil in its tolerability. Both can be given in a once per day dosing regimen. At maximum recommended doses, metrifonate and donepezil are both better tolerated than tacrine. The relative ease of use and good safety profile of metrifonate, along with donepezil, removes an important barrier to treatment that often arose with tacrine use.

There are no substantive criticisms of the studies1,2 reported here. They were conducted using a methodology similar to other CEI pivotal studies. There are obvious deficiencies, however, that are generic for current AD clinical trials. For example, compared with the overall duration of the disease, the period of therapy was short. The two articles do not tell how long to give CEIs. They did not compare metrifonate with already approved agents. The methods for measuring drug effects are not easily understood by those not involved in AD clinical trials.

In the United States, regulatory standards require that two principal outcome measures-an objective measure of cognitive function such as the ADAS-cog and a clinician's global assessment such as the CIBIC-show significant change for a drug to be approved for the treatment of AD. The methodology used in the current studies was constrained by these regulatory requirements. Is there a better way to measure anti-AD drug effects that might have greater ease of interpretation for nonexperts? Under certain circumstances, there probably is. The study by Sano et al.,19 in which milestones of severe dementia were the outcome measures, is one such example. However, these methods are not applicable to milder AD patients due to the length of the interval between study entry and the appearance of severe dementia. The use of measures like the ADAS-cog and the CIBIC, although divorced from methods usually used in routine practice, represent a compromise. They are broadly applicable, reliable, and valid,10,11 and therefore reasonably well suited for studies of 6 months' duration with mild-to-moderate AD patients. With more studies similar to those of Morris et al. and Cummings et al., clinicians will gain increasing familiarity with their quantitative aspects. When more potent anti-AD agents appear, neurologists will know what a"bigger" effect is.

An important question for practicing neurologists is whether the effects of metrifonate, tacrine, donepezil, and the others are big enough to justify their widespread use in patients with mild-to-moderate AD. Even if improvement does not occur, their effects in the clinical trials1,2,7-9 and elsewhere20 seem to translate into a delay in the symptomatic progression of AD for 6 to 12 months. The phase of the disease from diagnosis to severe dementia lasts roughly only 3 to 6 years.21 Even assuming that CEIs are strictly palliative and have no effect on the biologic progression of the disease, delay of symptomatic decline of 6 to 12 months is valuable to AD patients. Speculation that cholinesterases play a role in amyloidogenesis22,23 are not needed to bolster this argument. Given the tolerability of donepezil and metrifonate, one of these drugs should be recommended routinely to patients with mild-to-moderate AD. Furthermore, treatment should be continued until patients reach the stage of severe dementia.

Recommendation of CEIs does not imply that CEIs achieve the goal of definitive therapy in AD. Drug development programs must do better than the CEIs, not equal them. More potent palliative therapies are needed. However, a more fruitful approach to ameliorating the burden of AD may be through preventive therapies. Neuropathologic studies have shown that the morphologic antecedents of AD are present many years before the disease becomes clinically manifest.24 AD has a preclinical prodrome of at least several years' duration.25 Early detection and treatment of the preclinical AD syndrome might offer far better outcomes than treatment of symptomatic mild-to-moderate AD. Clinically apparent AD, however mild, represents "end-stage" disease. The effects of metrifonate and the other CEIs are undoubtedly constrained by the advanced degree of pathology present even in patients with mild, but symptomatic, AD.

Disclosure

Dr. Knopman has received compensation as a consultant to Parke-Davis, Athena Neuroscience, Eisai/Pfizer, Novartis, Wyeth-Ayerst, and Bayer, the sponsor of metrifonate. He is currently participating in clinical trials with Sigma-Tau, Bayer, Forest Laboratories, and Searle.

Footnotes

  • Accepted in final form February 23, 1998.

References

  1. 1.↵
    Cummings JL, Cyrus PA, Bieber F, et al. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology 1998;50:1214-1221.
    OpenUrlFREE Full Text
  2. 2.↵
    Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998;50:1222-1230.
    OpenUrlFREE Full Text
  3. 3.↵
    Becker RE, Colliver J, Elble R, et al. Effects of metrifonate, a long-acting cholinesterase inhibitor in Alzheimer disease: report of an open trial. Drug Dev Res 1990;19:425-434.
    OpenUrl
  4. 4.↵
    Bryson HM, Benfield P. Donepezil. Drugs Aging 1997;10:234-239.
    OpenUrl
  5. 5.
    Knopman DS. Drug evaluation: donepezil. Alzheimer's disease ID Research Alert 1997;2:157-161.
    OpenUrl
  6. 6.↵
    Davis KL, Powchik P. Tacrine. Lancet 1995;345:625-630.
    OpenUrlPubMed
  7. 7.↵
    Anand R, Enz A. Clinical confirmation of preclinical attributes: the ADENA program. Neurobiol Aging 1996;17(suppl 4):S87.
  8. 8.↵
    Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, The Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-145.
    OpenUrlFREE Full Text
  9. 9.↵
    Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991.
    OpenUrl
  10. 10.↵
    Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
    OpenUrlPubMed
  11. 11.↵
    Knopman DS, Knapp MJ, Gracon SI, Davis CS. The Clinician interview based impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 1994;44:2315-2321.
    OpenUrl
  12. 12.↵
    Thal LJ, Schwartz G, Sano M, et al. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Neurology 1996;47:1389-1395.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    Wilcock G, Wilkinson D. Galanthamine hydrobromide-Interim results of a group comparative, placebo controlled study of efficacy and safety in patients with a diagnosis of senile dementia of the Alzheimer type. Neurobiol Aging 1996;17(suppl 4):S144.
  14. 14.↵
    Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S33-S39.
  15. 15.↵
    Kaufer DI, Cummings JL, Christine D. Effects of tacrine on behavioral symptoms in Alzheimer's Disease: an open label study. J Geriatr Psychiatry Neurol 1996;9:1-6.
    OpenUrlPubMed
  16. 16.↵
    Raskind MA, Sadowsky CH, Sigmund WR, Beitler PJ, Auster SB. Effect of tacrine on language, praxis and noncognitive behavioral problems in Alzheimer disease. Arch Neurol 1997;54:836-840.
    OpenUrl
  17. 17.↵
    Bodick N, Offen W, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer Disease. Arch Neurol 1997;54:465-473.
    OpenUrl
  18. 18.↵
    Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
    OpenUrl
  19. 19.↵
    Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's Disease. N Engl J Med 1997;336:1216-1222.
    OpenUrlCrossRefPubMed
  20. 20.↵
    Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 1996;47:166-177.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    Heyman A, Peterson B, Fillenbaum G, Pieper C. Predictors of time to institutionalization of patients with Alzheimer's disease: the CERAD experience, part XVII. Neurology 1997;48:1304-1309.
    OpenUrlFREE Full Text
  22. 22.↵
    Lahiri DK, Farlow MR. Differential effect of tacrine and physostigmine on the secretion of the beta-amyloid precursor protein in cell lines. J Mol Neurosci 1996;7:41-49.
    OpenUrlPubMed
  23. 23.
    Guillozet AL, Smiley JF, Mash DC, Mesulam MM. Butyryl-cholinesterase in the life cycle of amyloid plaques. Ann Neurol 1997;42:909-918.
    OpenUrl
  24. 24.↵
    Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259.
    OpenUrl
  25. 25.↵
    Linn RT, Wolf PA, Bachman DL, et al. The 'preclinical phase' of probable Alzheimer's disease: a 13-year prospective study of the Framingham cohort. Arch Neurol 1995;52:485-490.
    OpenUrl
View Abstract

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Disclosure
    • Footnotes
    • References
  • Info & Disclosures
Advertisement

SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Dr. Jeffrey Allen and Dr. Nicholas Purcell

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Articles
    Metrifonate treatment of the cognitive deficits of Alzheimer's disease
    J. L. Cummings, P. A. Cyrus, F. Bieber et al.
    Neurology, May 01, 1998
  • Articles
    Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease
    John C. Morris, Pamela A. Cyrus, John Orazem et al.
    Neurology, May 01, 1998
  • Articles
    Metrifonate treatment of AD
    Influence of APOE genotype

    M.R. Farlow, P.A. Cyrus, A. Nadel et al.
    Neurology, December 01, 1999
  • Articles
    Pharmacologic treatment of cognition in Alzheimer's dementia
    Martin R. Farlow, Rebecca M. Evans et al.
    Neurology, July 01, 1998
Neurology: 100 (13)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise